Deflazacort

• CAT Number: A000573
• CAS Number: 14484-47-0
• Molecular Formula: C25H31NO6
• Molecular Weight: 441.5
• Purity: ≥95%
• Storage: 2-8°C
• IUPAC Name: [2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-6,14,17-trien-8-yl]-2-oxoethyl] acetate
• InChI: InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1
• InChIKey: FBHSPRKOSMHSIF-GRMWVWQJSA-N
• SMILES: CC1=NC2(C(O1)CC3C2(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)C(=O)COC(=O)C

Deflazacort (Cat No.:A000573) is a synthetic corticosteroid medication used for its anti-inflammatory and immunosuppressive effects. It is prescribed to treat a variety of inflammatory and autoimmune conditions, including allergies, asthma, rheumatoid arthritis, and inflammatory bowel disease. Deflazacort helps to reduce inflammation, swelling, and immune responses by modifying gene expression and inhibiting certain enzymes. It is often chosen for its lower potential to cause certain side effects compared to other corticosteroids.

Reference

1: Deflazacort (Emflaza) for Duchenne muscular dystrophy. Med Lett Drugs Ther.
2017 Sep 11;59(1529):153-154. PubMed PMID: 28880848.

2: Pereira JA, Mauricio AF, Marques MJ, Neto HS. Dual Therapy
Deflazacort/Doxycyclyne Is Better Than Deflazacort Monotherapy to Alleviate
Cardiomyopathy in Dystrophin-Deficient mdx Mice. J Cardiovasc Pharmacol Ther.
2017 Sep;22(5):458-466. doi: 10.1177/1074248416686189. Epub 2016 Dec 28. PubMed
PMID: 28793824.

3: Gupta N, Ganpati A, Mandal S, Mathew J, Goel R, Mathew AJ, Nair A, Ramasamy P,
Danda D. Mycophenolate mofetil and deflazacort combination in neuropsychiatric
lupus: a decade of experience from a tertiary care teaching hospital in southern
India. Clin Rheumatol. 2017 Aug 7. doi: 10.1007/s10067-017-3775-6. [Epub ahead of
print] PubMed PMID: 28785855.

4: Escudero AI, Marín P, Cárceles CM, Escudero E. Pharmacokinetics of deflazacort
in rabbits after intravenous and oral administration and its interaction with
erythromycin. J Vet Pharmacol Ther. 2017 Jul 25. doi: 10.1111/jvp.12442. [Epub
ahead of print] PubMed PMID: 28741668.

5: Jensen L, Petersson SJ, Illum NO, Laugaard-Jacobsen HC, Thelle T, Jørgensen
LH, Schrøder HD. Muscular response to the first three months of deflazacort
treatment in boys with Duchenne muscular dystrophy. J Musculoskelet Neuronal
Interact. 2017 Jun 1;17(2):8-18. PubMed PMID: 28574407; PubMed Central PMCID:
PMC5492315.

6: Deshmukh R, Sharma L, Tekade M, Kesharwani P, Trivedi P, Tekade RK. Force
degradation behavior of glucocorticoid deflazacort by UPLC: isolation,
identification and characterization of degradant by FTIR, NMR and mass analysis.
J Biomed Res. 2016 Mar;30(2):149-161. doi: 10.7555/JBR.30.20150074. Epub 2016 Feb
20. PubMed PMID: 28276670; PubMed Central PMCID: PMC4820892.

7: Traynor K. Deflazacort approved for Duchenne muscular dystrophy. Am J Health
Syst Pharm. 2017 Mar 15;74(6):368. doi: 10.2146/news170020. PubMed PMID:
28274975.

8: Parente L. Deflazacort: therapeutic index, relative potency and equivalent
doses versus other corticosteroids. BMC Pharmacol Toxicol. 2017 Jan 5;18(1):1.
doi: 10.1186/s40360-016-0111-8. PubMed PMID: 28057083; PubMed Central PMCID:
PMC5216559.

9: Raju CK, Pandey AK, Ghosh K, Pola A, Goud SK, Jaywant MA, Navalgund SG,
Surendranath KV. Isolation and structural characterization of novel photolytic
degradation impurities of Deflazacort using Q-TOF, 2D-NMR and FTIR. J Pharm
Biomed Anal. 2017 Jan 30;133:82-89. doi: 10.1016/j.jpba.2016.11.005. Epub 2016
Nov 8. PubMed PMID: 27843100.

10: Petnikota H, Madhuri V, Gangadharan S, Agarwal I, Antonisamy B. Retrospective
cohort study comparing the efficacy of prednisolone and deflazacort in children
with muscular dystrophy: A 6 years/’ experience in a South Indian teaching
hospital. Indian J Orthop. 2016 Sep;50(5):551-557. PubMed PMID: 27746500; PubMed
Central PMCID: PMC5017179.